BiotechTube

Mavacamten

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hypertrophic Cardiomyopathy

Conditions

Hypertrophic Cardiomyopathy

Trial Timeline

Oct 31, 2021 → Feb 28, 2022

NCT ID
NCT05135871

About Mavacamten

Mavacamten is a phase 1 stage product being developed by LianBio for Hypertrophic Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05135871. Target conditions include Hypertrophic Cardiomyopathy.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05135871Phase 1Completed

Competing Products

20 competing products in Hypertrophic Cardiomyopathy

See all competitors
ProductCompanyStageHype Score
Mavacamten + PlaceboLianBioPhase 3
69
CT-G20 + PlaceboCelltrionPhase 1
33
candesartanAstraZenecaPhase 2
52
LCZ696 + PlaceboNovartisPhase 2
52
Eleclazine + PlaceboGilead SciencesPhase 2/3
64
RanolazineGilead SciencesApproved
84
PF-06473871 + PF-06473871PfizerPhase 2
51
PF-06473871 + PF-06473871PfizerPhase 2
51
EXC 001 + EXC 001 + EXC 001 + EXC 001PfizerPhase 2
51
MavacamtenBristol Myers SquibbApproved
84
Mavacamten + PlaceboBristol Myers SquibbPhase 3
76
MavacamtenBristol Myers SquibbPre-clinical
22
MavacamtenBristol Myers SquibbPre-clinical
22
MavacamtenBristol Myers SquibbApproved
84
MYK-224Bristol Myers SquibbPhase 2
51
mavacamtenBristol Myers SquibbPhase 2/3
64
mavacamtenBristol Myers SquibbPhase 2
51
MavacamtenBristol Myers SquibbPre-clinical
22
MavacamtenBristol Myers SquibbPre-clinical
22
Mavacamten + PlaceboBristol Myers SquibbPhase 3
76

Other Products from LianBio

Mavacamten + PlaceboPhase 3
69
Lotilaner + Vehicle ControlPhase 3
69
InfigratinibPhase 2
44
InfigratinibPhase 2
44
BBP-398 + osimertinibPhase 1
25